Details
Once staging is complete, treatment planning must be individualized based on disease severity, subtype (wild-type vs. hereditary), and comorbid conditions. This lesson introduces the landscape of available therapies for transthyretin cardiac amyloidosis, including transthyretin stabilizers (tafamidis), gene silencers (patisiran, vutrisiran), and investigational agents. Supportive strategies, ranging from heart failure management to anticoagulation, are explored in context. Treatment options for light chain (AL) cardiac amyloidosis are also discussed, emphasizing the importance of multidisciplinary care. Learners will understand how to sequence therapies, monitor response, and adapt treatment to the Kenyan context.